BACKGROUND: Proteinase-activated receptor 2 (PAR2) is a G-protein-coupled receptor that is activated by several serine proteases. PAR2 activation in endometriotic stromal cells (ESCs) has been implicated in the development of endometriosis but the regulatory mechanism of PAR2 expression in ESC is unknown. Our objective was to study the mechanism by which PAR2 expression may be regulated in endometriotic lesions. METHODS: Primary cultures of ESCs were treated with transforming growth factor-β (TGF-β) 1, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and the expression of PAR2 was examined by real-time quantitative PCR. ESCs pretreated with or without TGF-β1 were treated with PAR2 agonist peptide (PAR2AP) and the secretion of the pro-endometriotic cytokine, IL-6, was measured using a specific enzyme-linked immunosorbent assay. Effects of TGF-β type 1 inhibitor, SB431542, and PAR2 small interfering RNA (siRNA) on the TGF-β1 stimulation of PAR2 gene expression and PAR2AP-induced IL-6 secretion were also evaluated. To study intracellular signaling, effects of inhibitors of mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase (PI3K) and of Smad4 siRNA on the TGF-β1-induced PAR2 gene expression were studied. RESULTS: Only TGF-β1, but neither TNF-α nor IL-1β, increased gene expression of PAR2. Activation of PAR2 with PAR2AP increased the secretion of IL-6 from ESCs. As expected, TGF-β1 pretreatment dose-dependently enhanced the PAR2AP-induced increase in IL-6 secretion from ESCs. Treatment of ESCs with the TGF-β type 1 inhibitor, SB431542, inhibited both TGF-β1-stimulation of PAR2 gene expression and PAR2AP-induced IL-6 secretion. Transfection of ESCs with PAR2 siRNA produced a similar inhibition of IL-6 secretion. The TGF-β1-induced increase in PAR2 gene expression was repressed by inhibition of p38 MAPK, p42/44 MAPK or PI3K, but not by knockdown of Smad4 expression. CONCLUSIONS: In view of significant roles of PAR2 and IL-6 in endometriosis, the TGF-β1-induced increase in PAR2 expression may be an elaborate mechanism that augments the progression of the disease.
BACKGROUND:Proteinase-activated receptor 2 (PAR2) is a G-protein-coupled receptor that is activated by several serine proteases. PAR2 activation in endometriotic stromal cells (ESCs) has been implicated in the development of endometriosis but the regulatory mechanism of PAR2 expression in ESC is unknown. Our objective was to study the mechanism by which PAR2 expression may be regulated in endometriotic lesions. METHODS: Primary cultures of ESCs were treated with transforming growth factor-β (TGF-β) 1, tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and the expression of PAR2 was examined by real-time quantitative PCR. ESCs pretreated with or without TGF-β1 were treated with PAR2 agonist peptide (PAR2AP) and the secretion of the pro-endometriotic cytokine, IL-6, was measured using a specific enzyme-linked immunosorbent assay. Effects of TGF-β type 1 inhibitor, SB431542, and PAR2 small interfering RNA (siRNA) on the TGF-β1 stimulation of PAR2 gene expression and PAR2AP-induced IL-6 secretion were also evaluated. To study intracellular signaling, effects of inhibitors of mitogen-activated protein kinases (MAPKs) and phosphoinositide 3-kinase (PI3K) and of Smad4 siRNA on the TGF-β1-induced PAR2 gene expression were studied. RESULTS: Only TGF-β1, but neither TNF-α nor IL-1β, increased gene expression of PAR2. Activation of PAR2 with PAR2AP increased the secretion of IL-6 from ESCs. As expected, TGF-β1 pretreatment dose-dependently enhanced the PAR2AP-induced increase in IL-6 secretion from ESCs. Treatment of ESCs with the TGF-β type 1 inhibitor, SB431542, inhibited both TGF-β1-stimulation of PAR2 gene expression and PAR2AP-induced IL-6 secretion. Transfection of ESCs with PAR2 siRNA produced a similar inhibition of IL-6 secretion. The TGF-β1-induced increase in PAR2 gene expression was repressed by inhibition of p38 MAPK, p42/44 MAPK or PI3K, but not by knockdown of Smad4 expression. CONCLUSIONS: In view of significant roles of PAR2 and IL-6 in endometriosis, the TGF-β1-induced increase in PAR2 expression may be an elaborate mechanism that augments the progression of the disease.
Authors: Franziska Zeeh; David Witte; Thomas Gädeken; Bernhard H Rauch; Evelin Grage-Griebenow; Nadja Leinung; Sofie Joline Fromm; Stephanie Stölting; Koichiro Mihara; Roland Kaufmann; Utz Settmacher; Hendrik Lehnert; Morley D Hollenberg; Hendrik Ungefroren Journal: Oncotarget Date: 2016-07-05
Authors: David Witte; Franziska Zeeh; Thomas Gädeken; Frank Gieseler; Bernhard H Rauch; Utz Settmacher; Roland Kaufmann; Hendrik Lehnert; Hendrik Ungefroren Journal: J Clin Med Date: 2016-11-30 Impact factor: 4.241
Authors: Hendrik Ungefroren; David Witte; Bernhard H Rauch; Utz Settmacher; Hendrik Lehnert; Frank Gieseler; Roland Kaufmann Journal: Int J Mol Sci Date: 2017-11-22 Impact factor: 5.923
Authors: Hendrik Ungefroren; Frank Gieseler; Roland Kaufmann; Utz Settmacher; Hendrik Lehnert; Bernhard H Rauch Journal: Int J Mol Sci Date: 2018-05-24 Impact factor: 5.923
Authors: G Goteri; E Altobelli; G Tossetta; A Zizzi; C Avellini; C Licini; T Lorenzi; M Castellucci; A Ciavattini; D Marzioni Journal: Eur J Histochem Date: 2015-12-09 Impact factor: 3.188
Authors: Parvin Kumar; Miranda Stiernborg; Anna Fogdell-Hahn; Kristoffer Månsson; Tomas Furmark; Daniel Berglind; Philippe A Melas; Yvonne Forsell; Catharina Lavebratt Journal: PLoS One Date: 2022-02-03 Impact factor: 3.240
Authors: Laura Mariuzzi; Rossana Domenis; Maria Orsaria; Stefania Marzinotto; Ambrogio P Londero; Michela Bulfoni; Veronica Candotti; Andrea Zanello; Maurizio Ballico; Maria C Mimmi; Angelo Calcagno; Diego Marchesoni; Carla Di Loreto; Antonio P Beltrami; Daniela Cesselli; Giorgia Gri Journal: Lab Invest Date: 2016-06-27 Impact factor: 5.662